Literature DB >> 22892452

Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC).

Baldev Vasir1, Corrine Zarwan, Rehan Ahmad, Keith D Crawford, Hassan Rajabi, Ken-Ichi Matsuoka, Jacalyn Rosenblatt, Zekui Wu, Heidi Mills, Donald Kufe, David Avigan.   

Abstract

The fowl pox vector expressing the tumor-associated antigens, mucin-1 and carcinoembryonic antigen in the context of costimulatory molecules (rF-PANVAC) has shown promise as a tumor vaccine. However, vaccine-mediated expansion of suppressor T-cell populations may blunt clinical efficacy. We characterized the cellular immune response induced by ex vivo dendritic cells (DCs) transduced with (rF)-PANVAC. Consistent with the functional characteristics of potent antigen-presenting cells, rF-PANVAC-DCs demonstrated strong expression of mucin-1 and carcinoembryonic antigen and costimulatory molecules, CD80, CD86, and CD83; decreased levels of phosphorylated STAT3, and increased levels of Tyk2, Janus kinase 2, and STAT1. rF-PANVAC-DCs stimulated expansion of tumor antigen-specific T cells with potent cytolytic capacity. However, rF-PANVAC-transduced DCs also induced the concurrent expansion of FOXP3 expressing CD4CD25 regulatory T cells (Tregs) that inhibited T-cell activation. Moreover, Tregs expressed high levels of Th2 cytokines [interleukin (IL)-10, IL-4, IL-5, and IL-13] together with phosphorylated STAT3 and STAT6. In contrast, the vaccine-expanded Treg population expressed high levels of Th1 cytokines IL-2 and interferon-γ and the proinflammatory receptor-related orphan receptor γt (RORγt) and IL-17A suggesting that these cells may share effector functions with conventional TH17 T cells. These data suggest that Tregs expanded by rF-PANVAC-DCs, exhibit immunosuppressive properties potentially mediated by Th2 cytokines, but simultaneous expression of Th1 and Th17-associated factors suggests a high degree of plasticity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22892452      PMCID: PMC3472644          DOI: 10.1097/CJI.0b013e31826a73de

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  59 in total

1.  Monocyte chemoattractant protein-1 selectively inhibits the acquisition of CD40 ligand-dependent IL-12-producing capacity of monocyte-derived dendritic cells and modulates Th1 immune response.

Authors:  Nemuko Omata; Motoko Yasutomi; Akiko Yamada; Hiromichi Iwasaki; Mitsufumi Mayumi; Yusei Ohshima
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

2.  Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.

Authors:  John L Marshall; James L Gulley; Philip M Arlen; Patricia K Beetham; Kwong-Yok Tsang; Rebecca Slack; James W Hodge; Sandra Doren; Douglas W Grosenbach; Jimmy Hwang; Evelyn Fox; Lauretta Odogwu; Susie Park; Dennis Panicali; Jeffrey Schlom
Journal:  J Clin Oncol       Date:  2004-12-21       Impact factor: 44.544

3.  Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.

Authors:  P Brossart; K S Heinrich; G Stuhler; L Behnke; V L Reichardt; S Stevanovic; A Muhm; H G Rammensee; L Kanz; W Brugger
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

Review 4.  Mechanisms and functional significance of tumour-induced dendritic-cell defects.

Authors:  Dmitry Gabrilovich
Journal:  Nat Rev Immunol       Date:  2004-12       Impact factor: 53.106

5.  Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.

Authors:  Allan J Pantuck; Arndt van Ophoven; Barbara J Gitlitz; Cho-Lea Tso; Bruce Acres; Patrick Squiban; Michael E Ross; Arie S Belldegrun; Robert A Figlin
Journal:  J Immunother       Date:  2004 May-Jun       Impact factor: 4.456

6.  Interferon-gamma inhibits STAT6 signal transduction and gene expression in human airway epithelial cells.

Authors:  Nicola M Heller; Satoshi Matsukura; Steve N Georas; Mark R Boothby; Paul B Rothman; Cristiana Stellato; Robert P Schleimer
Journal:  Am J Respir Cell Mol Biol       Date:  2004-08-05       Impact factor: 6.914

7.  Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.

Authors:  E Kass; J Schlom; J Thompson; F Guadagni; P Graziano; J W Greiner
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

Review 8.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

Authors:  Shimon Sakaguchi
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

9.  Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes.

Authors:  F Sallusto; D Lenig; C R Mackay; A Lanzavecchia
Journal:  J Exp Med       Date:  1998-03-16       Impact factor: 14.307

10.  Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

Authors:  Masaki Terabe; So Matsui; Jong-Myun Park; Mizuko Mamura; Nancy Noben-Trauth; Debra D Donaldson; Wanjun Chen; Sharon M Wahl; Steven Ledbetter; Bruce Pratt; John J Letterio; William E Paul; Jay A Berzofsky
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Enhancing poxvirus vectors vaccine immunogenicity.

Authors:  Juan García-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Interaction Between MUC1 and STAT1 Drives IFITM1 Overexpression in Aromatase Inhibitor-Resistant Breast Cancer Cells and Mediates Estrogen-Induced Apoptosis.

Authors:  Taylor E Escher; Asona J Lui; Eric S Geanes; Katherine R Walter; Ossama Tawfik; Christy R Hagan; Joan Lewis-Wambi
Journal:  Mol Cancer Res       Date:  2019-01-17       Impact factor: 5.852

Review 3.  Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment.

Authors:  Steven S Yu; Leslie K Ballas; Eila C Skinner; Tanya B Dorff; Sarmad Sadeghi; David I Quinn
Journal:  Clin Adv Hematol Oncol       Date:  2017-07

4.  Trial Watch: Toll-like receptor agonists in oncological indications.

Authors:  Fernando Aranda; Erika Vacchelli; Florine Obrist; Alexander Eggermont; Jérôme Galon; Catherine Sautès-Fridman; Isabelle Cremer; Jan Henrik Ter Meulen; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-08-01       Impact factor: 8.110

5.  A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.

Authors:  Patrick M Dillon; Gina R Petroni; Mark E Smolkin; David R Brenin; Kimberly A Chianese-Bullock; Kelly T Smith; Walter C Olson; Ibrahim S Fanous; Carmel J Nail; Christiana M Brenin; Emily H Hall; Craig L Slingluff
Journal:  J Immunother Cancer       Date:  2017-11-21       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.